Feline Degenerative Joint Disease (Osteoarthritis)

Feline Degenerative Joint Disease (Osteoarthritis; DJD/OA) is a chronic, progressive musculoskeletal disorder characterized by the gradual deterioration of articular cartilage, remodeling of subchondral bone, formation of osteophytes, and low-grade synovial inflammation within one or more joints. It is now recognized as one of the most prevalent and historically underdiagnosed conditions in domestic cats, with studies suggesting that radiographic evidence of OA is present in more than 60–90% of cats over 12 years of age. Despite its high prevalence, feline OA is frequently overlooked in clinical practice because cats tend to mask pain through behavioral adaptation rather than displaying the overt lameness commonly seen in dogs. The disease significantly impacts quality of life and is a leading cause of chronic pain in the geriatric cat population.

Primary vs. Secondary OA

Feline OA is classified as primary (idiopathic) when no underlying cause is identified — this is common in older cats and likely reflects cumulative biomechanical wear — or secondary when it arises from a predisposing condition such as:

• ·Hip dysplasia (notably in Maine Coon, Persian, and Siamese breeds)
• ·Patellar luxation
• ·Cranial cruciate ligament disease
• ·Intra-articular fractures or joint instability
• ·Osteochondrosis dissecans (OCD)
• ·Metabolic disorders (e.g., acromegaly, diabetes mellitus leading to cartilage changes)
• ·Obesity — excess body weight dramatically increases mechanical loading on joints

Pathophysiological Cascade

1. ·

   Cartilage degradation: Initial insult (mechanical overload, trauma, or metabolic change) disrupts chondrocyte homeostasis. Chondrocytes upregulate catabolic enzymes — matrix metalloproteinases (MMPs) and aggrecanases (ADAMTS) — that break down type II collagen and proteoglycans (aggrecan), the structural proteins that give cartilage its compressive resistance and water-retaining capacity.

2. ·

   Synovial inflammation: Cartilage matrix fragments act as danger-associated molecular patterns (DAMPs), triggering synoviocyte activation and the release of pro-inflammatory cytokines (interleukin-1β [IL-1β], tumor necrosis factor-α [TNF-α], and interleukin-6 [IL-6]). This creates a chronic low-grade synovitis that amplifies cartilage breakdown.

3. ·

   Subchondral bone remodeling: Loss of the cartilage "shock absorber" transfers mechanical stress to subchondral bone, stimulating osteoclast and osteoblast activity. This results in subchondral sclerosis, bone cyst formation, and periarticular osteophyte (bone spur) growth.

4. ·

   Joint capsule fibrosis and effusion: Chronic inflammation leads to thickening and fibrosis of the joint capsule, reducing range of motion. Synovial fluid composition becomes less viscous and loses its lubricating properties as hyaluronic acid concentrations fall.

5. ·

   Neurogenic sensitization: Persistent nociceptor activation within the joint capsule, subchondral bone, and periarticular tissues leads to central sensitization — a state of amplified pain perception even with minor stimuli (allodynia and hyperalgesia). This explains why even low-grade OA can produce significant functional impairment in cats.

Risk Factors

Special note — Scottish Fold cats: This breed carries a mutation in the TRPV4 gene causing osteochondrodysplasia, a severe, painful polyarthropathy affecting the distal limbs and tail that is distinct from typical OA and is present even in young cats.

Clinical Assessment

Diagnosis begins with a thorough history focusing on behavioral changes noticed by the owner, ideally using structured questionnaires such as the Feline Musculoskeletal Pain Index (FMPI) or owner-completed mobility checklists. Physical examination should include:

• ·Orthopedic examination: Systematic palpation of all joints for effusion, crepitus, reduced range of motion, periarticular thickening, and pain response on manipulation (joint flexion/extension). Cats often tense muscles rather than vocalize; subtle resistance is significant.
• ·Gait analysis: Assessed on a non-slip surface; may be normal in compensated cats.
• ·Muscle mass scoring: Comparison of bilateral hindlimb and forelimb musculature; asymmetric atrophy localizes affected joints.
• ·Body condition scoring (BCS): Critical because obesity exacerbates OA and must be addressed therapeutically.

Diagnostic Imaging

Radiography is the primary imaging modality and should include:

• ·Orthogonal views (minimum two projections per joint of interest)
• ·Sedation is strongly recommended for positioning quality and reduced patient stress
• ·Radiographic findings include: osteophyte formation, subchondral bone sclerosis, joint space narrowing, enthesophytes, periarticular soft tissue swelling, and intra-articular mineralizations
• ·Note: Radiographic severity correlates poorly with clinical signs — cats with severe radiographic changes may show subtle symptoms and vice versa

Advanced imaging:

• ·Computed Tomography (CT): Superior for complex joints (elbow, shoulder, tarsus) and for surgical planning; excellent bone detail
• ·Magnetic Resonance Imaging (MRI): Best for soft tissue evaluation (cartilage, synovium, tendons); limited availability in veterinary practice
• ·Ultrasonography: Useful for detecting joint effusion, synovial thickening, and guiding arthrocentesis; operator-dependent

Laboratory Tests

Routine bloodwork is not diagnostic for OA itself but is essential for:

1. ·Ruling out concurrent disease in geriatric patients (hyperthyroidism, chronic kidney disease, diabetes)
2. ·Pre-treatment safety screening prior to initiating NSAID therapy

Relevant panels and indicators include:

Synovial Fluid Analysis

Arthrocentesis (joint tap) is indicated when septic arthritis, immune-mediated polyarthritis, or neoplasia must be excluded. In uncomplicated OA, synovial fluid is:

• ·Typically clear to slightly turbid, pale yellow
• ·Mildly decreased viscosity
• ·Low nucleated cell count (< 2,000–5,000 cells/µL), predominantly mononuclear (macrophages/lymphocytes)
• ·No organisms on cytology or culture

Pain Scoring

The Feline Grimace Scale (FGS) and UNESP-Botucatu feline pain scale provide validated tools for assessing acute and chronic pain; they complement orthopedic findings and help monitor treatment response.

OA is a chronic, incurable disease; treatment goals are pain control, slowing progression, and preserving quality of life. A multimodal approach is strongly recommended.

1. Pharmacological Management

NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)

• ·Meloxicam (an oxicam-class COX-2 preferential inhibitor) is the most extensively studied and commonly used NSAID in cats; it is licensed for long-term use in cats in many countries (notably Europe and Australia)
• ·Robenacoxib (a selective COX-2 inhibitor) is approved for short-term use in cats in several countries
• ·Key caution: Long-term NSAID use requires regular monitoring of renal (BUN, CREA, SDMA) and hepatic (ALT, ALB) values every 3–6 months; NSAIDs are contraindicated or require extreme caution in cats with concurrent CKD, dehydration, or GI disease
• ·Use the lowest effective dose and re-evaluate periodically

Monoclonal Antibody Therapy (Novel & Emerging)

• ·Frunevetmab (Solensia®) — a felinized anti-nerve growth factor (anti-NGF) monoclonal antibody — is a landmark advance in feline OA management; administered as a monthly subcutaneous injection. NGF is a key mediator of OA-associated pain sensitization. It has demonstrated significant improvements in owner-assessed mobility and activity in clinical trials and is now approved in multiple countries. It does not carry renal risks associated with NSAIDs, making it suitable for cats with comorbid CKD.

Opioids and Other Analgesics

• ·Buprenorphine (partial μ-opioid agonist): Effective for moderate-to-severe pain; administered sublingually (transmucosal) in cats; most practical for short-to-medium-term use or flare management
• ·Tramadol: Weak opioid/SNRI mechanism; controversial efficacy in cats due to limited conversion to active M1 metabolite; used adjunctively in some protocols
• ·Gabapentin: α2δ calcium channel subunit ligand; useful for neuropathic/central sensitization pain components; increasingly used as adjunct therapy; also provides mild sedation that may reduce OA-associated anxiety and hyperalgesia
• ·Amantadine: NMDA receptor antagonist; used as add-on therapy for chronic pain with central sensitization; may help "reset" pain thresholds

Corticosteroids

• ·Intra-articular or systemic corticosteroids (e.g., methylprednisolone acetate) may be used short-term when NSAIDs are contraindicated (e.g., severe CKD)
• ·Long-term systemic use avoided due to risks of diabetes mellitus, immunosuppression, and muscle atrophy
• ·Intra-articular injections under sedation can provide localized relief

2. Nutraceuticals and Disease-Modifying Agents

3. Weight Management

• ·Critical intervention: Even modest weight reduction (10–15% of body weight) can meaningfully reduce joint loading and improve mobility scores
• ·Prescription weight-loss diets combined with caloric restriction and structured feeding schedules
• ·Regular reassessment of BCS; target BCS of 4–5/9

4. Environmental Modification ("Comfortable Living Adaptations")

• ·Low-sided or cut-away litter boxes (entry step height < 10 cm)
• ·Ramps or steps to favored resting spots to replace jumping
• ·Orthopedic or memory foam bedding in warm, draft-free locations
• ·Food and water bowls at an accessible height (raised slightly for cats with forelimb/neck involvement)
• ·Non-slip surfaces on floors (rubber mats, carpet runners)
• ·Multiple resting locations on a single level to reduce stair use

5. Physiotherapy and Rehabilitation

• ·Controlled exercise: Gentle, structured movement to maintain muscle mass and joint lubrication; cats rarely tolerate formal leash walking but can be encouraged with play
• ·Therapeutic laser (Low-Level Laser Therapy / Photobiomodulation): Class IV therapeutic laser has anti-inflammatory and analgesic effects; increasingly used in feline patients; well-tolerated
• ·Hydrotherapy / Underwater treadmill: Useful for building muscle with reduced joint loading; acceptance varies by cat
• ·Massage therapy: Gentle massage of periarticular musculature can reduce tension and improve local circulation

6. Surgical Options

Reserved for specific underlying conditions or refractory cases:

• ·Femoral head and neck ostectomy (FHO): For severe hip OA unresponsive to medical management
• ·Total hip replacement (THR): Technically feasible in cats; limited availability; high cost
• ·Arthrodesis (joint fusion): For end-stage OA in specific joints (e.g., carpus, tarsus); eliminates pain by eliminating motion
• ·Corrective osteotomy: For underlying structural abnormalities contributing to secondary OA

7. Acupuncture

• ·Veterinary acupuncture has growing evidence for pain relief in feline musculoskeletal disease; proposed mechanisms include endorphin release and local modulation of nociceptor activity; well-tolerated in many cats.

General Prognosis

Feline DJD/OA is a non-fatal, chronic, progressive disease and does not directly cause death. However, it significantly impacts quality of life, and severe, inadequately managed OA is one of the most common reasons owners elect euthanasia in geriatric cats when quality of life is deemed unacceptable.

Mortality rate attributable directly to OA is negligible (effectively 0% as a direct cause of death); the condition is not associated with reduced lifespan when pain is adequately managed. However, quality-of-life-related euthanasia is an important consideration in end-stage cases with multiple comorbidities.

Prognosis with Management

• ·With multimodal therapy (NSAIDs and/or anti-NGF therapy, weight management, environmental modification): The majority of cats show meaningful improvement in activity, mobility, and owner-assessed quality of life
• ·Anti-NGF monoclonal antibody therapy (frunevetmab) has demonstrated statistically significant improvements in mobility scores with monthly administration, even in cats with concurrent CKD
• ·Disease is not reversible — cartilage does not regenerate — but clinical signs can be managed effectively for months to years
• ·Comorbid conditions (CKD, hyperthyroidism, cardiac disease, cancer) are common in geriatric cats and complicate treatment; the overall prognosis is highly individualized

Prognostic Factors

Data limitation note: Long-term prospective survival studies specifically tracking mortality attributable to OA in cats are limited in the current veterinary literature. Most prognosis data is derived from clinical experience, treatment trial endpoints (activity scores, mobility indices), and quality-of-life assessments rather than formal survival analysis.

Complete prevention of primary OA is not currently possible, but several strategies can significantly reduce risk, delay onset, and slow progression:

Body Weight Management

• ·Maintain lean body condition (BCS 4–5/9) throughout life
• ·Obesity prevention is the single most impactful preventive measure; overweight cats have substantially higher OA prevalence and severity
• ·Neutered cats require caloric restriction; avoid ad libitum feeding

Early Screening and Monitoring

• ·Annual orthopedic examination for all cats > 7 years of age; every 6 months for cats > 10 years
• ·Radiographic screening of at-risk breeds (Maine Coon for hip dysplasia, Scottish Fold for osteochondrodysplasia) at a young age
• ·Use owner questionnaires (FMPI) at routine wellness visits to detect early behavioral changes before clinical signs are obvious

Genetic and Breeding Management

• ·Scottish Fold cats should not be bred (fold × fold matings) due to certainty of causing severe osteochondrodysplasia; fold × straight-eared pairings reduce but do not eliminate risk
• ·Screen breeding stock of predisposed breeds (Maine Coon, Persian) for hip dysplasia via PennHIP or OFA certification

Nutrition

• ·Feed age-appropriate, complete, and balanced diets
• ·Consider omega-3 fatty acid supplementation (EPA/DHA from fish oil) in cats > 7 years as a proactive anti-inflammatory strategy
• ·Avoid excessive mineral supplementation that may affect skeletal development in kittens

Joint Protection

• ·Provide appropriate environmental enrichment to maintain lean muscle mass and joint health without excessive high-impact activity (e.g., falling from heights)
• ·Address joint injuries or orthopedic abnormalities promptly and surgically when indicated to prevent secondary OA

Early Treatment of Predisposing Conditions

• ·Manage conditions known to predispose to secondary OA (hip dysplasia, patellar luxation, acromegaly) aggressively and early
• ·Control diabetes mellitus and other metabolic diseases that contribute to cartilage pathology

Note: There are no vaccines for OA. Prevention relies entirely on lifestyle, genetic, nutritional, and early diagnostic interventions.